|Henry Schein||Coming Soon|
|McGuff Medical Company||004400|
|McGuff Medical Company||009999|
|Certified Non-Genetically Modification Organism(GMO)||Yes||Yes|
|Generic Name||Ascorbic Acid||Ascorbic Acid|
|Medical License Required||Yes||Yes|
|FDA Country of Origin||United States of America||United States of America|
|Customs Country of Origin||United States of America||United States of America|
|Form||Pharmacy Bulk Package||Pharmacy Bulk Package|
|Strength||500 mg/mL||500 mg/mL|
|Size||50 mL||50 mL|
|Route of Administration||IV||IV|
|Therapeutic Class||Vitamin C||Vitamin C|
|Derived from genetically engineered plant||No||No|
|Source of Vitamin C||Proprietary||Proprietary|
|Storage Temperature||Store in refrigerator at 2º to 8º C (36º to 46º F)||Store in refrigerator at 2º to 8º C (36º to 46º F)|
|Protect from Freezing||Yes||Yes|
|Expiration Date||2 years from date of manufacture||2 years from date of manufacture|
|Protect from Light||Yes||Yes|
|Vial Height||3 in||3 in|
|Vial Diameter||1.67 in||1.67 in|
|Vial Stopper Diameter||0.785 in||0.785 in|
|Weight||0.32 lbs||6.95 lbs|
|Height||3 in||3 in|
|Length||1.75 in||8.5 in|
|Width||1.75 in||8.5 in|
|Sold As||Individual Vial||25 Vials per Tray|
ASCOR® is vitamin C indicated for the short term (up to 1 week) treatment of
scurvy in adult and pediatric patients age 5 months and older for whom oral
administration is not possible, insufficient or contraindicated.
Limitations of Use:
ASCOR® is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.
Administration site reactions include pain and swelling.
ASCOR® should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR® may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache.
Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid. ASCOR® is not indicated for prolonged administration. The maximum recommended duration is one week.
In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred.
Ascorbic acid may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing, nitrite and bilirubin levels, and leucocyte count testing. If possible, laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion of ASCOR®.
Please see accompanying Full Prescribing Information for ASCOR®.
The information contained in this section of the site is intended for U.S. healthcare professionals only.